What You Should Know:
- Lys Therapeutics, a French biotechnology company, has announced a $5M grant award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
- The significant funding, part of MJFF’s Therapeutic Pipeline Program, will accelerate the clinical development of LYS241, a first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders. The grant will support the completion of preclinical development
Read More
neuropsychiatric disorders
PsychoGenics Launches AI Platform to Revolutionize Drug Discovery
What You Should Know:
- PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform.
The platform supports phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
How eCube Works
eCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained
Read More
Mindstrong Health, Takeda Partner to Develop Digital Biomarkers for Mental Health Conditions
Mindstrong Health, a digital health startup transforming the diagnosis and treatment of neuropsychiatric disorders, has entered into a partnership with Takeda Pharmaceutical Company Limited to explore the development of digital biomarkers for selected mental health conditions, in particular schizophrenia and treatment-resistant depression.In this decade, neuropsychiatric disorders represent the largest source of medical disability for people under age 50. The costs are among the highest of all
Read More
